Summary

The high-throughput screening (HTS) market is expected to reach USD 45.90 billion in 2031 from USD 27.66 billion in 2026, growing at a CAGR of 10.7% during the forecast period. Factors such as the rising adoption of open innovation models, increasing government funding and venture capital investments, and higher R&D spending by pharmaceutical and biotechnology companies. Technological advancements in automation, high-content screening, cell-based assays, label-free detection, and AI-enabled data analysis are further improving screening efficiency and supporting wider adoption of HTS platforms across drug discovery workflows.

offering, the products segment accounted for the largest share of the high-throughput screening (HTS) market in 2025.
Based on offering, the high-throughput screening (HTS) market is segmented into products and services. In 2025, the products segment held the largest share of the high-throughput screening (HTS) market. This is driven by recurring demand for assay kits, reagents, consumables, microplates, compound libraries, instruments, software, and automation platforms. The segment remains dominant because HTS workflows require continuous use of consumables and integrated instruments throughout assay development, screening, data analysis, and hit confirmation. Strong adoption of automated liquid handlers, microplate readers, high-content imaging systems, and assay-ready kits further supports the revenue contribution of products in the HTS market.

By application, the drug discovery & development segment accounted for the largest share of the high-throughput screening (HTS) market in 2025.
By application, the high-throughput screening (HTS) market is divided into drug discovery & development, basic research & functional genomics, toxicology & safety screening, precision medicine & biomarker discovery, stem cell & regenerative medicine research, and other applications. In 2025, the drug discovery & development segment held the largest share of the high-throughput screening (HTS) market, as HTS is widely used to screen large compound libraries, identify hits, validate targets, and support lead optimization. Pharmaceutical and biotechnology companies continue to rely on HTS platforms to improve early-stage discovery productivity and reduce the time required to move candidates into preclinical development. The segment also benefits from the growing use of phenotypic screening, cell-based assays, 3D models, and high-content imaging to identify more biologically relevant drug candidates.

The Asia Pacific region is expected to grow at the highest CAGR in the high-throughput screening (HTS) market from 2026 to 2031.
The high-throughput screening (HTS) market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by expanding pharmaceutical and biotechnology R&D activity, growing CRO presence, and increasing investments in drug discovery infrastructure. Countries such as China, India, Japan, and South Korea are strengthening their screening capabilities through rising research funding, outsourcing demand, and the adoption of automated laboratory technologies. The region is also benefiting from cost-efficient research operations, expanding biotech start-up activity, and increasing partnerships between global pharma companies and local discovery service providers.
The primary interviews conducted for this report can be categorized as follows:

? By Respondent: Supply Side (80%) and Demand Side (20%)
? By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
? By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), the Middle East & Africa (5%)

Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity, Inc. (US), Tecan Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Corning Incorporated (US), Mettler-Toledo International Inc. (US), Lonza Group (Switzerland), Waters Corporation (US), Sartorius AG (Germany), Eppendorf SE (Germany), Porvair Plc (UK), Greiner AG (Austria), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), and Hamilton Company (US) are some of the key companies offering HTS solutions.

Research Coverage
This research report categorizes the high-throughput screening (HTS) market by offering (products and services), products by type (instruments; reagents, kits, and consumables; software & informatics; and services), products by technology (biochemical screening technologies, cell-based screening technologies, high-content screening (HCS) technologies, label-free screening technologies, microfluidic & miniaturized screening technologies, 3D cell culture & advanced cellular model technologies, ultra-high-throughput & automation technologies, and AI-enabled & computational screening technologies), products by workflow (assay development & optimization, compound library preparation, high-throughput screening, data analysis & hit identification, hit confirmation, hit validation & characterization), products by end user (pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and other end users), services by type (assay development & optimization services, compound library management services, primary screening services, secondary screening & hit confirmation services, hit validation & characterization services, data analysis & informatics services, and other services), services by end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), application (drug discovery & development, basic research & functional genomics, toxicology & safety screening, precision medicine & biomarker discovery, stem cell & regenerative medicine research, and other applications), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the high-throughput screening (HTS) market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product/service portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the high-throughput screening (HTS) market. This report includes a competitive analysis of top players and upcoming startups in the high-throughput screening (HTS) market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.

Key Benefits of Buying the Report
This report offers a comprehensive overview of the high-throughput screening (HTS) market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (growing adoption of open innovative models, growing R&D funding and increasing public & private investments, growing adoption of lab automation and robotic screening platforms, and increasing outsourcing of screening activities to CROs and HTS service providers), restraints (high costs associated with HTS instruments and complexity in assay development and validation), opportunities (increasing adoption of HTS technologies in emerging markets and growing application of HTS in drug repurposing and personalized medicine), and challenges (complexity in data management & analysis, standardization challenges in 3D, organoid, and image-based assays)
? Product/Service Development/Innovation: Detailed insights on newly launched products/services, and technological assessment of the high-throughput screening (HTS) market.
? Market Development: Comprehensive information about lucrative markets; the report analyzes the high-throughput screening (HTS) market across varied regions.
? Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the high-throughput screening (HTS) market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity, Inc. (US), Tecan Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Corning Incorporated (US), Mettler-Toledo International Inc. (US), Lonza Group (Switzerland), Waters Corporation (US), Sartorius AG (Germany), Eppendorf SE (Germany), Porvair Plc (UK), Greiner AG (Austria), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), and Hamilton Company (US), among others, in the high-throughput screening (HTS) market.
The report also helps stakeholders understand trends in the high-throughput screening (HTS) market and provides information on key drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their strategies, product/service launches, acquisitions, partnerships, collaborations, recent activities, investments, funding, brand and product comparisons, vendor evaluations, and financial metrics of the HTS sector market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 60
1.1 STUDY OBJECTIVES 60
1.2 MARKET DEFINITION 60
1.3 STUDY SCOPE 60
1.3.1 MARKET SEGMENTATION & REGIONS COVERED 61
1.3.2 INCLUSIONS & EXCLUSIONS 62
1.3.3 YEARS CONSIDERED 64
1.3.4 CURRENCY CONSIDERED 64
1.4 STAKEHOLDERS 64
1.5 SUMMARY OF CHANGES 65
2 EXECUTIVE SUMMARY 66
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 66
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 67
2.3 DISRUPTIVE TRENDS IN HIGH-THROUGHPUT SCREENING MARKET 68
2.4 HIGH-GROWTH SEGMENTS 69
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 70
3 PREMIUM INSIGHTS 72
3.1 HIGH-THROUGHPUT SCREENING MARKET OVERVIEW 72
3.2 NORTH AMERICA: HIGH-THROUGHPUT SCREENING MARKET,
BY PRODUCT TYPE AND COUNTRY 73
3.3 HIGH-THROUGHPUT SCREENING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 74
3.4 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET SHARE, BY END USER,
2026 VS 2031 (%) 75
4 MARKET OVERVIEW 76
4.1 INTRODUCTION 76
4.2 MARKET DYNAMICS 77
4.2.1 DRIVERS 78
4.2.1.1 Growing adoption of open innovative models 78
4.2.1.2 Technological advancements 78
4.2.1.3 Growing R&D funding and increasing public & private investments 79
4.2.1.4 Growing adoption of lab automation & robotic screening platforms 79
4.2.1.5 Increasing outsourcing of screening activities to CROs & CDMOs 80
4.2.2 RESTRAINTS 81
4.2.2.1 High costs associated with HTS instruments 81
4.2.2.2 Complexity in assay development and validation 81
4.2.3 OPPORTUNITIES 82
4.2.3.1 Increasing adoption of HTS technologies in emerging markets 82
4.2.3.2 Growing application of HTS in drug repurposing and personalized medicine 82
4.2.3.3 Expansion of CRISPR, RNAi, and functional genomics screening 82
4.2.4 CHALLENGES 83
4.2.4.1 Complexity in data management and analysis 83
4.3 UNMET NEEDS & WHITE SPACES 83
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 84
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 85
5 INDUSTRY TRENDS 86
5.1 PORTER’S FIVE FORCES ANALYSIS 86
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 87
5.1.2 BARGAINING POWER OF SUPPLIERS 87
5.1.3 BARGAINING POWER OF BUYERS 87
5.1.4 THREAT OF SUBSTITUTES 87
5.1.5 THREAT OF NEW ENTRANTS 88
5.2 MACROECONOMIC OUTLOOK 88
5.2.1 INTRODUCTION 88
5.2.2 GDP TRENDS & FORECAST 88
5.2.3 TRENDS IN GLOBAL HIGH-THROUGHPUT SCREENING INDUSTRY 89
5.3 VALUE CHAIN ANALYSIS 89
5.4 ECOSYSTEM ANALYSIS 91
5.5 PRICING ANALYSIS 93
5.5.1 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS,
BY KEY PLAYER, 2023?2025 93
5.5.2 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS,
BY REGION, 2023?2025 95
5.6 TRADE ANALYSIS 96
5.6.1 IMPORT SCENARIO (HS CODE 902730 & 902781) 96
5.6.2 EXPORT SCENARIO (HS CODE 902730& 902781) 99
5.7 KEY CONFERENCES & EVENTS, 2026?2027 102
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 103
5.9 INVESTMENT & FUNDING SCENARIO 103
5.10 IMPACT OF 2025 US TARIFFS ON HIGH-THROUGHPUT SCREENING (HTS) MARKET 104
5.10.1 INTRODUCTION 104
5.10.2 KEY TARIFF RATES 105
5.10.3 PRICE IMPACT ANALYSIS 106
5.10.4 IMPACT ON COUNTRIES/REGIONS 106
5.10.4.1 US 106
5.10.4.2 Europe 107
5.10.4.3 Asia Pacific 107
?
5.10.5 IMPACT ON END-USE INDUSTRIES 107
5.10.5.1 Pharmaceutical & biotechnology companies 108
5.10.5.2 CROs & CDMOs 108
5.10.5.3 Academic & research institutes 108
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT,
PATENTS, AND INNOVATIONS 109
6.1 TECHNOLOGICAL ANALYSIS 109
6.1.1 KEY EMERGING TECHNOLOGIES 109
6.1.1.1 High-content screening 109
6.1.1.2 Label-free detection 109
6.1.1.3 Microfluidics 110
6.1.2 COMPLEMENTARY TECHNOLOGIES 110
6.1.2.1 Laboratory automation & robotic integration 110
6.1.2.2 Mass spectrometry 110
6.1.2.3 Flow cytometry 110
6.1.3 ADJACENT TECHNOLOGIES 111
6.1.3.1 Fragment-based drug discovery 111
6.1.3.2 Bioinformatics & cheminformatics 111
6.2 TECHNOLOGY/PRODUCT ROADMAP 112
6.3 PATENT ANALYSIS 112
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR HIGH-THROUGHPUT SCREENING PATENTS, 2015?2025 113
6.4 FUTURE APPLICATIONS 115
6.5 IMPACT OF AI/GEN AI ON HIGH-THROUGHPUT SCREENING (HTS) MARKET 116
6.5.1 BEST PRACTICES IN HTS WORKFLOW 117
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN HIGH-THROUGHPUT SCREENING (HTS) MARKET 118
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 119
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN HIGH-THROUGHPUT SCREENING (HTS) MARKET 119
7 SUSTAINABILITY & REGULATORY LANDSCAPE 120
7.1 REGIONAL REGULATIONS & COMPLIANCE 120
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 120
7.1.2 INDUSTRY STANDARDS 122
7.2 SUSTAINABILITY INITIATIVES 124
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 124
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 124
?
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 125
8.1 DECISION-MAKING PROCESS 125
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 125
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 125
8.2.2 KEY BUYING CRITERIA, BY END USER 126
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 127
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 127
8.5 MARKET PROFITABILITY 128
9 HIGH-THROUGHPUT SCREENING MARKET, BY OFFERING 129
9.1 INTRODUCTION 130
9.2 PRODUCTS 130
9.2.1 RECURRING CONSUMABLES DEMAND, AUTOMATION UPGRADES, AND ADVANCED SCREENING PLATFORMS TO DRIVE MARKET GROWTH 130
9.3 SERVICES 134
9.3.1 RISING OUTSOURCING OF ASSAY DEVELOPMENT, PRIMARY SCREENING, AND DATA ANALYSIS TO DRIVE GROWTH OF HTS SERVICES MARKET 134
10 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TYPE 138
10.1 INTRODUCTION 139
10.2 REAGENTS, KITS, AND CONSUMABLES 139
10.2.1 SCREENING ASSAY KITS 143
10.2.1.1 Cell-based assays 146
10.2.1.1.1 Cell viability assays 149
10.2.1.1.1.1 Increasing use of viability readouts across oncology and toxicity screening to sustain assay kit demand 149
10.2.1.1.2 Cytotoxicity assays 152
10.2.1.1.2.1 Rising focus on early toxicity detection to improve lead selection and reduce drug development risk 152
10.2.1.1.3 Reporter gene assays 155
10.2.1.1.3.1 Growing use of pathway-specific functional readouts to strengthen reporter gene assay adoption 155
10.2.1.1.4 Other cell-based assays 158
10.2.1.2 Biochemical assays 161
10.2.1.2.1 Enzyme assays 164
10.2.1.2.1.1 Broad use of enzyme activity profiling in target-based drug discovery to sustain demand for enzyme assay kits 164
10.2.1.2.2 Kinase assays 167
10.2.1.2.2.1 Continued investment in targeted kinase inhibitor discovery to drive kinase assay kit demand 167
10.2.1.2.3 Binding assays 169
10.2.1.2.3.1 Rising use of target engagement and affinity profiling to improve hit validation quality 169
10.2.1.2.4 Other biochemical assays 172
10.2.1.3 Other assays & kits 175
10.2.2 BIOLOGICAL & CELL CULTURE REAGENTS 178
10.2.2.1 Rising use of disease-relevant cellular models to strengthen demand for biological and cell culture reagents 178
10.2.3 COMPOUND LIBRARIES 181
10.2.3.1 Expansion of focused and repurpose libraries to support compound library demand 181
10.2.4 DETECTION REAGENTS 184
10.2.4.1 Increasing adoption of fluorescence, luminescence, and biomarker-based readouts to drive detection reagent use 184
10.2.5 3D CELL CULTURE PRODUCTS 186
10.2.5.1 Scaffold-based 3D cell culture products 189
10.2.5.1.1 Rising demand for matrix-supported disease models to drive scaffold-based 3D culture product growth 189
10.2.5.2 Scaffold-free 3D cell culture products 193
10.2.5.2.1 Increasing use of spheroid-based screening to support scaffold-free 3D culture product adoption 193
10.2.5.3 Other 3D cell culture products 196
10.2.6 OTHER HTS CONSUMABLES 199
10.3 INSTRUMENTS 202
10.3.1 DETECTION & IMAGING SYSTEMS 205
10.3.1.1 Microplate readers 208
10.3.1.1.1 Growing use of multiplexed biochemical and cell-based assays to support microplate reader demand 208
10.3.1.2 High-content screening (HCS) & imaging systems 212
10.3.1.2.1 Increasing adoption of phenotypic screening and AI-based cellular analysis to drive growth of HCS systems 212
10.3.1.3 Cell analysis systems 215
10.3.1.3.1 Growing use of cell-based screening and functional biology assays to strengthen demand for cell analysis systems 215
10.3.1.4 Label-free detection systems 218
10.3.1.4.1 Rising need for real-time biomolecular interaction analysis to support adoption of label-free detection systems 218
10.3.1.5 Microfluidic & miniaturized screening systems 221
10.3.1.5.1 Assay miniaturization to drive adoption of microfluidic screening systems 221
10.3.2 LIQUID HANDLING & AUTOMATION SYSTEMS 225
10.3.2.1 Increasing assay miniaturization and workflow standardization to drive growth of liquid handling & automation systems 225
10.3.3 ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS 228
10.3.3.1 Rising deployment of end-to-end laboratory automation systems to accelerate robotic HTS platform adoption 228
10.3.4 OTHER HTS INSTRUMENTS 231
10.4 SOFTWARE & INFORMATICS 234
10.4.1 BIOINFORMATICS TOOLS TO HELP TURN RAW DATA INTO MEANINGFUL INSIGHTS 234
11 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TECHNOLOGY 238
11.1 INTRODUCTION 239
11.2 CELL-BASED SCREENING TECHNOLOGIES 240
11.2.1 INCREASING ADOPTION OF PHYSIOLOGICALLY RELEVANT PHENOTYPIC SCREENING WORKFLOWS TO STRENGTHEN CELL-BASED TECHNOLOGY DEMAND 240
11.3 ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES 243
11.3.1 GROWING DEMAND FOR SCALABLE ROBOTIC INFRASTRUCTURE & INTEGRATED AUTOMATION PLATFORMS TO SUPPORT MARKET GROWTH 243
11.4 HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES 247
11.4.1 RISING ADOPTION OF AI-POWERED PHENOTYPIC IMAGING AND MULTIPARAMETRIC CELLULAR PROFILING TO ACCELERATE HCS TECHNOLOGY GROWTH 247
11.5 BIOCHEMICAL SCREENING TECHNOLOGIES 250
11.5.1 CONTINUED EXPANSION OF TARGET-BASED DRUG DISCOVERY PROGRAMS TO SUSTAIN BIOCHEMICAL SCREENING PRODUCT DEMAND 250
11.6 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES 254
11.6.1 RISING ADOPTION OF ORGANOIDS, SPHEROIDS, AND TISSUE-LIKE SCREENING SYSTEMS TO ACCELERATE 3D CELLULAR TECHNOLOGY GROWTH 254
11.7 LABEL-FREE SCREENING TECHNOLOGIES 257
11.7.1 INCREASING USE OF REAL-TIME BINDING KINETICS AND BIOPHYSICAL PROFILING TO SUPPORT LABEL-FREE SCREENING ADOPTION 257
11.8 OTHER HTS TECHNOLOGIES 261
12 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY WORKFLOW 264
12.1 INTRODUCTION 265
12.2 PRIMARY SCREENING 265
12.2.1 LARGE-SCALE COMPOUND SCREENING REQUIREMENTS TO SUSTAIN PRODUCT DEMAND ACROSS PRIMARY HTS WORKFLOWS 265
12.3 ASSAY DEVELOPMENT & OPTIMIZATION 269
12.3.1 RISING NEED FOR ROBUST, MINIATURIZED, AND AUTOMATION-COMPATIBLE ASSAYS TO SUPPORT ASSAY DEVELOPMENT PRODUCT DEMAND 269
12.4 HIT CONFIRMATION/SECONDARY SCREENING 272
12.4.1 RISING FOCUS ON HIT QUALITY ASSESSMENT AND FALSE-POSITIVE REDUCTION TO SUPPORT SECONDARY SCREENING PRODUCT DEMAND 272
12.5 DATA ANALYSIS & HIT IDENTIFICATION 276
12.5.1 INCREASING INTEGRATION OF AI-DRIVEN ANALYTICS AND IMAGE-BASED SCREENING DATA TO ACCELERATE HIT IDENTIFICATION WORKFLOWS 276
12.6 COMPOUND LIBRARY PREPARATION 279
12.6.1 EXPANSION OF LARGE-SCALE AND FOCUSED SCREENING LIBRARIES TO STRENGTHEN DEMAND FOR COMPOUND PREPARATION PRODUCTS 279
12.7 HIT VALIDATION & CHARACTERIZATION 282
12.7.1 GROWING FOCUS ON PHENOTYPIC CHARACTERIZATION WORKFLOWS TO DRIVE HIT VALIDATION PRODUCT DEMAND 282
?
13 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY END USER 286
13.1 INTRODUCTION 287
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 287
13.2.1 SUSTAINED BIOPHARMA R&D INVESTMENT AND AUTOMATION-LED DRUG DISCOVERY TO DRIVE HTS PRODUCT ADOPTION 287
13.3 CROS & CDMOS 291
13.3.1 RISING DISCOVERY OUTSOURCING AND CRO PLATFORM EXPANSION TO ACCELERATE HTS PRODUCT DEMAND 291
13.4 ACADEMIC & RESEARCH INSTITUTES 294
13.4.1 PUBLIC RESEARCH FUNDING AND TRANSLATIONAL BIOLOGY PROGRAMS TO SUPPORT HTS PRODUCT UPTAKE IN RESEARCH INSTITUTES 294
13.5 OTHER END USERS 298
14 HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY TYPE 301
14.1 INTRODUCTION 302
14.2 PRIMARY SCREENING SERVICES 303
14.2.1 RISING HIGH-VOLUME SCREENING REQUIREMENTS TO DRIVE GROWTH OF PRIMARY HTS SCREENING SERVICES 303
14.3 ASSAY DEVELOPMENT & OPTIMIZATION SERVICES 306
14.3.1 INCREASING DEMAND FOR CUSTOMIZED AND MINIATURIZED ASSAYS TO SUPPORT ASSAY DEVELOPMENT SERVICE ADOPTION 306
14.4 SECONDARY SCREENING & HIT CONFIRMATION SERVICES 309
14.4.1 INCREASING EMPHASIS ON HIT VALIDATION AND SELECTIVITY ASSESSMENT TO SUPPORT SECONDARY SCREENING SERVICES 309
14.5 HIT VALIDATION & CHARACTERIZATION SERVICES 312
14.5.1 GROWING NEED FOR MECHANISM-OF-ACTION PROFILING TO STRENGTHEN HIT CHARACTERIZATION SERVICE ADOPTION 312
14.6 COMPOUND LIBRARY MANAGEMENT SERVICES 315
14.6.1 EXPANSION OF LARGE-SCALE SCREENING LIBRARIES TO STRENGTHEN DEMAND FOR COMPOUND MANAGEMENT SERVICES 315
14.7 DATA ANALYSIS & INFORMATICS SERVICES 318
14.7.1 GROWING ADOPTION OF AI-ENABLED SCREENING ANALYTICS AND IMAGE-BASED DATA INTERPRETATION TO DRIVE HTS INFORMATICS SERVICES GROWTH 318
14.8 OTHER HTS SERVICES 322
15 HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY END USER 325
15.1 INTRODUCTION 326
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 326
15.2.1 INCREASING COMPLEXITY OF DRUG DISCOVERY WORKFLOWS TO STRENGTHEN OUTSOURCING OF HTS SERVICES BY PHARMA AND
BIOTECH COMPANIES 326
15.3 ACADEMIC & RESEARCH INSTITUTES 330
15.3.1 LIMITED IN-HOUSE AUTOMATION CAPACITY TO DRIVE ACADEMIC OUTSOURCING OF HTS SERVICES 330
15.4 OTHER END USERS 333
16 HIGH-THROUGHPUT SCREENING MARKET, BY APPLICATION 336
16.1 INTRODUCTION 337
16.2 DRUG DISCOVERY & DEVELOPMENT 338
16.2.1 INCREASING PHARMACEUTICAL R&D INVESTMENTS AND EXPANSION OF TARGET-BASED AND PHENOTYPIC DRUG DISCOVERY PROGRAMS TO DRIVE MARKET GROWTH 338
16.3 BASIC RESEARCH & FUNCTIONAL GENOMICS 341
16.3.1 GROWING ADOPTION OF CRISPR SCREENING, FUNCTIONAL GENOMICS, AND DISEASE PATHWAY CHARACTERIZATION TO DRIVE HTS DEMAND 341
16.4 TOXICOLOGY & SAFETY SCREENING 345
16.4.1 INCREASING EMPHASIS ON PREDICTIVE TOXICOLOGY AND REGULATORY PRESSURE TO REDUCE ANIMAL TESTING TO ACCELERATE HTS ADOPTION 345
16.5 PRECISION MEDICINE & BIOMARKER DISCOVERY 348
16.5.1 EXPANSION OF BIOMARKER-GUIDED THERAPEUTICS AND PERSONALIZED MEDICINE PIPELINES TO DRIVE RAPID GROWTH IN PRECISION MEDICINE SCREENING APPLICATIONS 348
16.6 STEM CELL & REGENERATIVE MEDICINE RESEARCH 351
16.6.1 GROWING DEVELOPMENT OF CELL THERAPIES AND REGENERATIVE MEDICINE PRODUCTS IS SUPPORTING HTS ADOPTION IN STEM CELL RESEARCH 351
16.7 OTHER APPLICATIONS 354
17 HIGH-THROUGHPUT SCREENING MARKET, BY REGION 357
17.1 INTRODUCTION 358
17.2 NORTH AMERICA 359
17.2.1 US 368
17.2.1.1 Advanced automation, strong drug discovery infrastructure, and AI-enabled screening workflows to support market growth 368
17.2.2 CANADA 375
17.2.2.1 Academic screening infrastructure to support market growth 375
17.3 EUROPE 383
17.3.1 GERMANY 392
17.3.1.1 Increasing product launches and investments to boost market growth 392
17.3.2 UK 399
17.3.2.1 Industrial-scale screening access and academic HTS infrastructure to support market 399
17.3.3 FRANCE 406
17.3.3.1 Large pharmaceutical R&D expenditure to drive market growth 406
17.3.4 ITALY 414
17.3.4.1 Functional genomics and automated screening platforms to fuel growth 414
17.3.5 SPAIN 421
17.3.5.1 Academic screening platforms, chemical biology networks, and assay automation to boost market 421
17.3.6 REST OF EUROPE 427
17.4 ASIA PACIFIC 435
17.4.1 CHINA 444
17.4.1.1 Automation-led drug discovery and CRO-led screening capacity expansion to support growth of market 444
17.4.2 JAPAN 451
17.4.2.1 Advanced screening platforms and integrated drug discovery partnerships to support market growth 451
17.4.3 INDIA 458
17.4.3.1 Automation-led CRO expansion and biopharma R&D infrastructure growth to fuel market 458
17.4.4 AUSTRALIA 465
17.4.4.1 Robotic screening infrastructure and translational drug discovery programs to drive market growth 465
17.4.5 SOUTH KOREA 472
17.4.5.1 AI-enhanced screening platforms and translational R&D collaborations to favor market growth 472
17.4.6 REST OF ASIA PACIFIC (ROAPAC) 479
17.5 LATIN AMERICA 486
17.5.1 BRAZIL 494
17.5.1.1 Automated bioassay infrastructure and disease-focused discovery programs to drive growth 494
17.5.2 MEXICO 501
17.5.2.1 Cost-efficient discovery capacity, antimicrobial research, and automated assay adoption to drive growth 501
17.5.3 REST OF LATIN AMERICA 508
17.6 MIDDLE EAST 515
17.6.1 GCC COUNTRIES 522
17.6.1.1 Saudi Arabia 530
17.6.1.1.1 Growing pharmaceuticals industry to support market growth 530
17.6.1.2 UAE 537
17.6.1.2.1 Precision medicine investment, automated laboratory infrastructure, and AI-enabled discovery workflows to boost market growth 537
17.6.1.3 Rest of GCC Countries 544
17.6.2 REST OF MIDDLE EAST 550
17.7 AFRICA 558
17.7.1 INFECTIOUS DISEASE RESEARCH AND SHARED DISCOVERY NETWORKS TO AID MARKET GROWTH 558
?
18 COMPETITIVE LANDSCAPE 565
18.1 OVERVIEW 565
18.2 KEY PLAYER STRATEGY/RIGHT TO WIN 565
18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HIGH-THROUGHPUT SCREENING (HTS) MARKET 566
18.3 REVENUE ANALYSIS, 2021?2025 567
18.4 MARKET SHARE ANALYSIS, 2025 568
18.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2025 571
18.5.1 STARS 571
18.5.2 EMERGING LEADERS 571
18.5.3 PERVASIVE PLAYERS 571
18.5.4 PARTICIPANTS 572
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 573
18.5.5.1 Company footprint 573
18.5.5.2 Region footprint 574
18.5.5.3 Offering footprint 575
18.5.5.4 Product type footprint 576
18.5.5.5 Application footprint 577
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 578
18.6.1 PROGRESSIVE COMPANIES 578
18.6.2 RESPONSIVE COMPANIES 578
18.6.3 DYNAMIC COMPANIES 578
18.6.4 STARTING BLOCKS 578
18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 580
18.6.5.1 Detailed list of key startups/SMEs 580
18.6.5.2 Competitive benchmarking of key startups/SMEs 581
18.7 COMPANY VALUATION & FINANCIAL METRICS 581
18.7.1 FINANCIAL METRICS 581
18.7.2 COMPANY VALUATION 582
18.8 BRAND/PRODUCT/SERVICE COMPARISON 583
18.9 COMPETITIVE SCENARIO 584
18.9.1 PRODUCT LAUNCHES 584
18.9.2 DEALS 585
18.9.3 EXPANSIONS 586
19 COMPANY PROFILES 587
19.1 KEY PLAYERS 587
19.1.1 THERMO FISHER SCIENTIFIC INC. 587
19.1.1.1 Business overview 587
19.1.1.2 Products & services offered 588
19.1.1.3 Recent developments 591
19.1.1.3.1 Product launches 591
19.1.1.3.2 Deals 593
19.1.1.3.3 Expansions 594
19.1.1.4 MnM view 595
19.1.1.4.1 Right to win 595
19.1.1.4.2 Strategic choices 595
19.1.1.4.3 Weaknesses & competitive threats 595
19.1.2 DANAHER CORPORATION 596
19.1.2.1 Business overview 596
19.1.2.2 Products & services offered 597
19.1.2.3 Recent developments 601
19.1.2.3.1 Product & service launches 601
19.1.2.3.2 Deals 601
19.1.2.4 MnM view 602
19.1.2.4.1 Right to win 602
19.1.2.4.2 Strategic choices 602
19.1.2.4.3 Weaknesses & competitive threats 602
19.1.3 MERCK KGAA 603
19.1.3.1 Business overview 603
19.1.3.2 Products & services offered 604
19.1.3.3 Recent developments 606
19.1.3.3.1 Deals 606
19.1.3.3.2 Expansions 607
19.1.3.3.3 Other developments 607
19.1.3.4 MnM view 607
19.1.3.4.1 Right to win 607
19.1.3.4.2 Strategic choices 608
19.1.3.4.3 Weaknesses & competitive threats 608
19.1.4 AGILENT TECHNOLOGIES, INC. 609
19.1.4.1 Business overview 609
19.1.4.2 Products & services offered 610
19.1.4.3 Recent developments 614
19.1.4.3.1 Product launches & upgrades 614
19.1.4.3.2 Deals 615
19.1.4.3.3 Expansions 616
19.1.4.3.4 Other developments 616
19.1.4.4 MnM view 617
19.1.4.4.1 Right to win 617
19.1.4.4.2 Strategic choices 617
19.1.4.4.3 Weaknesses & competitive threats 617
?
19.1.5 REVVITY, INC. 618
19.1.5.1 Business overview 618
19.1.5.2 Products & services offered 619
19.1.5.3 Recent developments 622
19.1.5.3.1 Product launches 622
19.1.5.3.2 Deals 623
19.1.5.4 MnM view 623
19.1.5.4.1 Right to win 623
19.1.5.4.2 Strategic choices 623
19.1.5.4.3 Weaknesses & competitive threats 623
19.1.6 TECAN GROUP LTD. 624
19.1.6.1 Business overview 624
19.1.6.2 Products & service offered 625
19.1.6.3 Recent developments 627
19.1.6.3.1 Product launches 627
19.1.6.3.2 Deals 627
19.1.7 BIO-RAD LABORATORIES, INC. 628
19.1.7.1 Business overview 628
19.1.7.2 Products & services offered 629
19.1.7.3 Recent developments 632
19.1.7.3.1 Product launches 632
19.1.8 CORNING INCORPORATED 633
19.1.8.1 Business overview 633
19.1.8.2 Products & services offered 634
19.1.9 METTLER-TOLEDO INTERNATIONAL INC. 636
19.1.9.1 Business overview 636
19.1.9.2 Products & services offered 637
19.1.10 LONZA GROUP 639
19.1.10.1 Business overview 639
19.1.10.2 Products & services offered 640
19.1.11 WATERS CORPORATION 641
19.1.11.1 Business overview 641
19.1.11.2 Products & services offered 642
19.1.11.3 Recent developments 644
19.1.11.3.1 Product launches 644
19.1.11.3.2 Deals 645
19.1.12 SARTORIUS AG 646
19.1.12.1 Business overview 646
19.1.12.2 Products & services offered 647
19.1.12.3 Recent developments 652
19.1.12.3.1 Product launches 652
19.1.12.3.2 Deals 652
19.1.12.3.3 Expansions 652
19.1.13 EPPENDORF SE 653
19.1.13.1 Business overview 653
19.1.13.2 Products & services offered 654
19.1.13.3 Recent developments 656
19.1.13.3.1 Product launches 656
19.1.13.3.2 Deals 656
19.1.13.3.3 Expansions 657
19.1.14 PORVAIR PLC 658
19.1.14.1 Business overview 658
19.1.14.2 Products & services offered 660
19.1.15 GREINER AG 661
19.1.15.1 Business overview 661
19.1.15.2 Products & services offered 662
19.1.16 CHARLES RIVER LABORATORIES 665
19.1.16.1 Business overview 665
19.1.16.2 products & services offered 667
19.1.16.3 Recent developments 667
19.1.16.3.1 Deals 667
19.1.17 EUROFINS SCIENTIFIC 668
19.1.17.1 Business overview 668
19.1.17.2 Products & services offered 669
19.1.17.3 Recent developments 671
19.1.17.3.1 Service launches 671
19.1.17.3.2 Deals 671
19.1.17.3.3 Expansions 671
19.1.18 HAMILTON COMPANY 672
19.1.18.1 Business overview 672
19.1.18.2 Products & services offered 672
19.1.18.3 Recent developments 673
19.1.18.3.1 Product launches 673
19.1.18.3.2 Deals 674
19.1.19 AURORA BIOMED INC. 675
19.1.19.1 Business overview 675
19.1.19.2 Products & services offered 675
19.1.20 GILSON INCORPORATED 676
19.1.20.1 Business overview 676
19.1.20.2 Products & services offered 676
19.1.21 BRAND GMBH + CO KG 682
19.1.21.1 Business overview 682
19.1.21.2 Products & services offered 682
?
19.2 OTHER PLAYERS 686
19.2.1 BMG LABTECH GMBH 686
19.2.2 DIANA BIOTECHNOLOGIES, A.S. 687
19.2.3 CREATIVE BIOLABS 687
19.2.4 HIGHRES BIOSOLUTIONS 689
19.2.5 BIOMAT SRL 690
19.2.6 AXXAM S.P.A. 691
19.2.7 SYGNATURE DISCOVERY LIMITED 692
19.2.8 CROWN BIOSCIENCE 694
20 RESEARCH METHODOLOGY 695
20.1 RESEARCH DATA 695
20.1.1 SECONDARY DATA 696
20.1.1.1 Key secondary sources 696
20.1.1.2 Key data from secondary research 696
20.1.2 PRIMARY DATA 697
20.1.2.1 Key primary participants 697
20.1.2.2 Breakdown of primary interviews 697
20.1.2.3 Key data from primary sources 698
20.2 MARKET SIZE ESTIMATION 698
20.2.1 GLOBAL HIGH-THROUGHPUT SCREENING MARKET ESTIMATION, 2025 698
20.2.1.1 Approach 1: Company revenue analysis-based estimation
(bottom-up) 699
20.2.1.2 Approach 2: Primary research 700
20.2.1.2.1 Key industry insights 701
20.2.1.3 Approach 3: MnM repository analysis 701
20.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 702
20.3 MARKET GROWTH RATE PROJECTIONS 704
20.4 DATA TRIANGULATION 706
20.5 RESEARCH ASSUMPTIONS 707
20.6 RESEARCH LIMITATIONS AND RISK ASSESSMENT 708
21 APPENDIX 709
21.1 DISCUSSION GUIDE 709
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 715
21.3 CUSTOMIZATION OPTIONS 717
21.4 RELATED REPORTS 717
21.5 AUTHOR DETAILS 718

ページTOPに戻る

List of Tables/Graphs

TABLE 1 HIGH-THROUGHPUT SCREENING (HTS) MARKET: INCLUSIONS & EXCLUSIONS 62
TABLE 2 HIGH-THROUGHPUT SCREENING (HTS) MARKET:
IMPACT ANALYSIS OF MARKET DYNAMICS 77
TABLE 3 HIGH-THROUGHPUT SCREENING (HTS) MARKET:
IMPACT OF PORTER’S FIVE FORCES 87
TABLE 4 HIGH-THROUGHPUT SCREENING (HTS) MARKET: ROLE IN ECOSYSTEM 92
TABLE 5 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY KEY PLAYER,
2023?2025 (USD) 93
TABLE 6 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY REGION,
2023?2025 (USD) 95
TABLE 7 IMPORT VALUE FOR HS CODE 902730, 2021?2025 (USD THOUSAND) 96
TABLE 8 IMPORT VOLUME FOR HS CODE 902730, 2021?2025 (TONS) 97
TABLE 9 IMPORT VALUE FOR HS CODE 902781, 2022?2025 (USD THOUSAND) 98
TABLE 10 IMPORT VOLUME FOR HS CODE 902781, 2022?2025 (UNITS) 99
TABLE 11 EXPORT VALUE FOR HS CODE 902730, BY COUNTRY,
2021?2025 (USD THOUSAND) 99
TABLE 12 EXPORT VOLUME FOR HS CODE 902730, BY COUNTRY, 2021?2025 (TONS) 100
TABLE 13 EXPORT VALUE FOR HS CODE 902781, 2022?2025 (USD THOUSAND) 101
TABLE 14 EXPORT VOLUME FOR HS CODE 902781, 2022?2025 (UNITS) 101
TABLE 15 HIGH-THROUGHPUT SCREENING (HTS) MARKET:
KEY CONFERENCES & EVENTS, 2026?2027 102
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 105
TABLE 17 HIGH-THROUGHPUT SCREENING (HTS) MARKET:
INDICATIVE LIST OF PATENTS, 2026 114
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN HIGH-THROUGHPUT
SCREENING (HTS) MARKET 118
TABLE 19 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN HIGH-THROUGHPUT SCREENING 119
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 120
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 120
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 121
TABLE 23 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 122
TABLE 24 US FOOD AND DRUG ADMINISTRATION: MEDICAL DEVICE CLASSIFICATION 123
TABLE 25 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 123
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 125
TABLE 27 KEY BUYING CRITERIA, BY END USER 126
TABLE 28 HIGH-THROUGHPUT SCREENING MARKET, BY OFFERING,
2024?2031 (USD MILLION) 130
TABLE 29 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY REGION,
2024?2031 (USD MILLION) 131
TABLE 30 NORTH AMERICA: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 131
TABLE 31 EUROPE: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 132
TABLE 32 ASIA PACIFIC: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 132
TABLE 33 LATIN AMERICA: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 133
TABLE 34 MIDDLE EAST: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET,
BY REGION, 2024?2031 (USD MILLION) 133
TABLE 35 GCC COUNTRIES: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 133
TABLE 36 HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY REGION,
2024?2031 (USD MILLION) 134
TABLE 37 NORTH AMERICA: HIGH-THROUGHPUT SCREENING SERVICES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 135
TABLE 38 EUROPE: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 135
TABLE 39 ASIA PACIFIC: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 136
TABLE 40 LATIN AMERICA: HIGH-THROUGHPUT SCREENING SERVICES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 136
TABLE 41 MIDDLE EAST: HIGH-THROUGHPUT SCREENING SERVICES MARKET,
BY REGION, 2024?2031 (USD MILLION) 136
TABLE 42 GCC COUNTRIES: HIGH-THROUGHPUT SCREENING SERVICES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 137
TABLE 43 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TYPE,
2024?2031 (USD MILLION) 139
TABLE 44 HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION,
2024?2031 (USD MILLION) 140
TABLE 45 NORTH AMERICA: HTS REAGENTS, KITS, AND CONSUMABLES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 140
TABLE 46 EUROPE: HTS REAGENTS, KITS, AND CONSUMABLES MARKET,
2024?2031 (USD MILLION) 141
TABLE 47 ASIA PACIFIC: HTS REAGENTS, KITS, AND CONSUMABLES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 141
TABLE 48 LATIN AMERICA: HTS REAGENTS, KITS, AND CONSUMABLES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 142
TABLE 49 MIDDLE EAST: HTS REAGENTS, KITS, AND CONSUMABLES MARKET,
BY REGION, 2024?2031 (USD MILLION) 142
TABLE 50 GCC COUNTRIES: HTS REAGENTS, KITS, AND CONSUMABLES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 142
TABLE 51 HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY TYPE,
2024?2031 (USD MILLION) 143
TABLE 52 SCREENING ASSAY KITS MARKET, BY REGION, 2024?2031 (USD MILLION) 143
TABLE 53 NORTH AMERICA: SCREENING ASSAY KITS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 144
TABLE 54 EUROPE: SCREENING ASSAY KITS MARKET, 2024?2031 (USD MILLION) 144
TABLE 55 ASIA PACIFIC: SCREENING ASSAY KITS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 145
TABLE 56 LATIN AMERICA: SCREENING ASSAY KITS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 145
TABLE 57 MIDDLE EAST: SCREENING ASSAY KITS MARKET, BY REGION,
2024?2031 (USD MILLION) 145
TABLE 58 GCC COUNTRIES: SCREENING ASSAY KITS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 146
TABLE 59 SCREENING ASSAY KITS MARKET, BY TYPE, 2024?2031 (USD MILLION) 146
TABLE 60 CELL-BASED ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 147
TABLE 61 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 147
TABLE 62 EUROPE: CELL-BASED ASSAYS MARKET, 2024?2031 (USD MILLION) 147
TABLE 63 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 148
TABLE 64 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 148
TABLE 65 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY REGION,
2024?2031 (USD MILLION) 148
TABLE 66 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 149
TABLE 67 CELL-BASED ASSAYS MARKET, BY TYPE, 2024?2031 (USD MILLION) 149
TABLE 68 CELL VIABILITY ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 150
TABLE 69 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 150
TABLE 70 EUROPE: CELL VIABILITY ASSAYS MARKET, 2024?2031 (USD MILLION) 150
TABLE 71 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 151
TABLE 72 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 151
TABLE 73 MIDDLE EAST: CELL VIABILITY ASSAYS MARKET, BY REGION,
2024?2031 (USD MILLION) 151
TABLE 74 GCC COUNTRIES: CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 152
TABLE 75 CYTOTOXICITY ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 152
TABLE 76 NORTH AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 153
TABLE 77 EUROPE: CYTOTOXICITY ASSAYS MARKET, 2024?2031 (USD MILLION) 153
TABLE 78 ASIA PACIFIC: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 153
TABLE 79 LATIN AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 154
TABLE 80 MIDDLE EAST: CYTOTOXICITY ASSAYS MARKET, BY REGION,
2024?2031 (USD MILLION) 154
TABLE 81 GCC COUNTRIES: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 154
TABLE 82 REPORTER GENE ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 155
TABLE 83 NORTH AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 155
TABLE 84 EUROPE: REPORTER GENE ASSAYS MARKET, 2024?2031 (USD MILLION) 156
TABLE 85 ASIA PACIFIC: REPORTER GENE ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 156
TABLE 86 LATIN AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 157
TABLE 87 MIDDLE EAST: REPORTER GENE ASSAYS MARKET, BY REGION,
2024?2031 (USD MILLION) 157
TABLE 88 GCC COUNTRIES: REPORTER GENE ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 157
TABLE 89 OTHER CELL-BASED ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 158
TABLE 90 NORTH AMERICA: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 158
TABLE 91 EUROPE: OTHER CELL-BASED ASSAYS MARKET, 2024?2031 (USD MILLION) 159
TABLE 92 ASIA PACIFIC: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 159
TABLE 93 LATIN AMERICA: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 160
TABLE 94 MIDDLE EAST: OTHER CELL-BASED ASSAYS MARKET, BY REGION,
2024?2031 (USD MILLION) 160
TABLE 95 GCC COUNTRIES: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 160
TABLE 96 BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 161
TABLE 97 NORTH AMERICA: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 161
TABLE 98 EUROPE: BIOCHEMICAL ASSAYS MARKET, 2024?2031 (USD MILLION) 162
TABLE 99 ASIA PACIFIC: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 162
TABLE 100 LATIN AMERICA: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 163
TABLE 101 MIDDLE EAST: BIOCHEMICAL ASSAYS MARKET, BY REGION,
2024?2031 (USD MILLION) 163
TABLE 102 GCC COUNTRIES: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 163
TABLE 103 BIOCHEMICAL ASSAYS MARKET, BY TYPE, 2024?2031 (USD MILLION) 164
TABLE 104 ENZYME ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 164
TABLE 105 NORTH AMERICA: ENZYME ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 165
TABLE 106 EUROPE: ENZYME ASSAYS MARKET, 2024?2031 (USD MILLION) 165
TABLE 107 ASIA PACIFIC: ENZYME ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 165
TABLE 108 LATIN AMERICA: ENZYME ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 166
TABLE 109 MIDDLE EAST: ENZYME ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 166
TABLE 110 GCC COUNTRIES: ENZYME ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 166
TABLE 111 KINASE ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 167
TABLE 112 NORTH AMERICA: KINASE ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 167
TABLE 113 EUROPE: KINASE ASSAYS MARKET, 2024?2031 (USD MILLION) 168
TABLE 114 ASIA PACIFIC: KINASE ASSAYS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 168
TABLE 115 LATIN AMERICA: KINASE ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 168
TABLE 116 MIDDLE EAST: KINASE ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 169
TABLE 117 GCC COUNTRIES: KINASE ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 169
TABLE 118 BINDING ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 170
TABLE 119 NORTH AMERICA: BINDING ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 170
TABLE 120 EUROPE: BINDING ASSAYS MARKET, 2024?2031 (USD MILLION) 170
TABLE 121 ASIA PACIFIC: BINDING ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 171
TABLE 122 LATIN AMERICA: BINDING ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 171
TABLE 123 MIDDLE EAST: BINDING ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 171
TABLE 124 GCC COUNTRIES: BINDING ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 172
TABLE 125 OTHER BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024?2031 (USD MILLION) 172
TABLE 126 NORTH AMERICA: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 173
TABLE 127 EUROPE: OTHER BIOCHEMICAL ASSAYS MARKET, 2024?2031 (USD MILLION) 173
TABLE 128 ASIA PACIFIC: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 174
TABLE 129 LATIN AMERICA: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 174
TABLE 130 MIDDLE EAST: OTHER BIOCHEMICAL ASSAYS MARKET, BY REGION,
2024?2031 (USD MILLION) 174
TABLE 131 GCC COUNTRIES: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 175
TABLE 132 OTHER ASSAYS & KITS MARKET, BY REGION, 2024?2031 (USD MILLION) 175
TABLE 133 NORTH AMERICA: OTHER ASSAYS & KITS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 176
TABLE 134 EUROPE: OTHER ASSAYS & KITS MARKET, 2024?2031 (USD MILLION) 176
TABLE 135 ASIA PACIFIC: OTHER ASSAYS & KITS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 176
TABLE 136 LATIN AMERICA: OTHER ASSAYS & KITS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 177
TABLE 137 MIDDLE EAST: OTHER ASSAYS & KITS MARKET, BY REGION,
2024?2031 (USD MILLION) 177
TABLE 138 GCC COUNTRIES: OTHER ASSAYS & KITS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 177
TABLE 139 BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY REGION,
2024?2031 (USD MILLION) 178
TABLE 140 NORTH AMERICA: BIOLOGICAL & CELL CULTURE REAGENTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 178
TABLE 141 EUROPE: BIOLOGICAL & CELL CULTURE REAGENTS MARKET,
2024?2031 (USD MILLION) 179
TABLE 142 ASIA PACIFIC: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 179
TABLE 143 LATIN AMERICA: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 180
TABLE 144 MIDDLE EAST: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 180
TABLE 145 GCC COUNTRIES: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 180
TABLE 146 COMPOUND LIBRARIES MARKET, BY REGION, 2024?2031 (USD MILLION) 181
TABLE 147 NORTH AMERICA: COMPOUND LIBRARIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 181
TABLE 148 EUROPE: COMPOUND LIBRARIES MARKET, 2024?2031 (USD MILLION) 182
TABLE 149 ASIA PACIFIC: COMPOUND LIBRARIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 182
TABLE 150 LATIN AMERICA: COMPOUND LIBRARIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 183
TABLE 151 MIDDLE EAST: COMPOUND LIBRARIES MARKET, BY REGION,
2024?2031 (USD MILLION) 183
TABLE 152 GCC COUNTRIES: COMPOUND LIBRARIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 183
TABLE 153 DETECTION REAGENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 184
TABLE 154 NORTH AMERICA: DETECTION REAGENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 184
TABLE 155 EUROPE: DETECTION REAGENTS MARKET, 2024?2031 (USD MILLION) 185
TABLE 156 ASIA PACIFIC: DETECTION REAGENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 185
TABLE 157 LATIN AMERICA: DETECTION REAGENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 185
TABLE 158 MIDDLE EAST: DETECTION REAGENTS MARKET, BY REGION,
2024?2031 (USD MILLION) 186
TABLE 159 GCC COUNTRIES: DETECTION REAGENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 186
TABLE 160 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024?2031 (USD MILLION) 187
TABLE 161 NORTH AMERICA: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 187
TABLE 162 EUROPE: 3D CELL CULTURE PRODUCTS MARKET, 2024?2031 (USD MILLION) 187
TABLE 163 ASIA PACIFIC: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 188
TABLE 164 LATIN AMERICA: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 188
TABLE 165 MIDDLE EAST: 3D CELL CULTURE PRODUCTS MARKET, BY REGION,
2024?2031 (USD MILLION) 188
TABLE 166 GCC COUNTRIES: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 189
TABLE 167 3D CELL CULTURE PRODUCTS MARKET, BY TYPE, 2024?2031 (USD MILLION) 189
TABLE 168 SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY REGION,
2024?2031 (USD MILLION) 190
TABLE 169 NORTH AMERICA: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 190
TABLE 170 EUROPE: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET,
2024?2031 (USD MILLION) 191
TABLE 171 ASIA PACIFIC: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 191
TABLE 172 LATIN AMERICA: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 192
TABLE 173 MIDDLE EAST: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET,
BY REGION, 2024?2031 (USD MILLION) 192
TABLE 174 GCC COUNTRIES: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 192
TABLE 175 SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY REGION,
2024?2031 (USD MILLION) 193
TABLE 176 NORTH AMERICA: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 193
TABLE 177 EUROPE: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET,
2024?2031 (USD MILLION) 194
TABLE 178 ASIA PACIFIC: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 194
TABLE 179 LATIN AMERICA: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 195
TABLE 180 MIDDLE EAST: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET,
BY REGION, 2024?2031 (USD MILLION) 195
TABLE 181 GCC COUNTRIES: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 195
TABLE 182 OTHER 3D CELL CULTURE PRODUCTS MARKET, BY REGION,
2024?2031 (USD MILLION) 196
TABLE 183 NORTH AMERICA: OTHER 3D CELL CULTURE PRODUCTS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 196
TABLE 184 EUROPE: OTHER 3D CELL CULTURE PRODUCTS MARKET,
2024?2031 (USD MILLION) 197
TABLE 185 ASIA PACIFIC: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 197
TABLE 186 LATIN AMERICA: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 198
TABLE 187 MIDDLE EAST: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY REGION,
2024?2031 (USD MILLION) 198
TABLE 188 GCC COUNTRIES: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 198
TABLE 189 OTHER HTS CONSUMABLES MARKET, BY REGION, 2024?2031 (USD MILLION) 199
TABLE 190 NORTH AMERICA: OTHER HTS CONSUMABLES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 199
TABLE 191 EUROPE: OTHER HTS CONSUMABLES MARKET, 2024?2031 (USD MILLION) 200
TABLE 192 ASIA PACIFIC: OTHER HTS CONSUMABLES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 200
TABLE 193 LATIN AMERICA: OTHER HTS CONSUMABLES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 201
TABLE 194 MIDDLE EAST: OTHER HTS CONSUMABLES MARKET, BY REGION,
2024?2031 (USD MILLION) 201
TABLE 195 GCC COUNTRIES: OTHER HTS CONSUMABLES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 201
TABLE 196 HTS INSTRUMENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 202
TABLE 197 NORTH AMERICA: HTS INSTRUMENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 203
TABLE 198 EUROPE: HTS INSTRUMENTS MARKET, 2024?2031 (USD MILLION) 203
TABLE 199 ASIA PACIFIC: HTS INSTRUMENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 203
TABLE 200 LATIN AMERICA: HTS INSTRUMENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 204
TABLE 201 MIDDLE EAST: HTS INSTRUMENTS MARKET, BY REGION,
2024?2031 (USD MILLION) 204
TABLE 202 GCC COUNTRIES: HTS INSTRUMENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 204
TABLE 203 HTS INSTRUMENTS MARKET, BY TYPE, 2024?2031 (USD MILLION) 205
TABLE 204 DETECTION & IMAGING SYSTEMS MARKET, BY REGION,
2024?2031 (USD MILLION) 206
TABLE 205 NORTH AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 206
TABLE 206 EUROPE: DETECTION & IMAGING SYSTEMS MARKET, 2024?2031 (USD MILLION) 206
TABLE 207 ASIA PACIFIC: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 207
TABLE 208 LATIN AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 207
TABLE 209 MIDDLE EAST: DETECTION & IMAGING SYSTEMS MARKET, BY REGION,
2024?2031 (USD MILLION) 207
TABLE 210 GCC COUNTRIES: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 208
TABLE 211 DETECTION & IMAGING SYSTEMS MARKET, BY TYPE, 2024?2031 (USD MILLION) 208
TABLE 212 MICROPLATE READERS MARKET, BY REGION, 2024?2031 (USD MILLION) 209
TABLE 213 NORTH AMERICA: MICROPLATE READERS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 209
TABLE 214 EUROPE: MICROPLATE READERS MARKET, 2024?2031 (USD MILLION) 210
TABLE 215 ASIA PACIFIC: MICROPLATE READERS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 210
TABLE 216 LATIN AMERICA: MICROPLATE READERS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 211
TABLE 217 MIDDLE EAST: MICROPLATE READERS MARKET, BY REGION,
2024?2031 (USD MILLION) 211
TABLE 218 GCC COUNTRIES: MICROPLATE READERS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 211
TABLE 219 HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY REGION,
2024?2031 (USD MILLION) 212
TABLE 220 NORTH AMERICA: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 213
TABLE 221 EUROPE: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET,
2024?2031 (USD MILLION) 213
TABLE 222 ASIA PACIFIC: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 214
TABLE 223 LATIN AMERICA: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 214
TABLE 224 MIDDLE EAST: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET,
BY REGION, 2024?2031 (USD MILLION) 214
TABLE 225 GCC COUNTRIES: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 215
TABLE 226 CELL ANALYSIS SYSTEMS MARKET, BY REGION, 2024?2031 (USD MILLION) 215
TABLE 227 NORTH AMERICA: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 216
TABLE 228 EUROPE: CELL ANALYSIS SYSTEMS MARKET, 2024?2031 (USD MILLION) 216
TABLE 229 ASIA PACIFIC: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 217
TABLE 230 LATIN AMERICA: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 217
TABLE 231 MIDDLE EAST: CELL ANALYSIS SYSTEMS MARKET, BY REGION,
2024?2031 (USD MILLION) 217
TABLE 232 GCC COUNTRIES: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 218
TABLE 233 LABEL-FREE DETECTION SYSTEMS MARKET, BY REGION,
2024?2031 (USD MILLION) 219
TABLE 234 NORTH AMERICA: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 219
TABLE 235 EUROPE: LABEL-FREE DETECTION SYSTEMS MARKET, 2024?2031 (USD MILLION) 219
TABLE 236 ASIA PACIFIC: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 220
TABLE 237 LATIN AMERICA: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 220
TABLE 238 MIDDLE EAST: LABEL-FREE DETECTION SYSTEMS MARKET, BY REGION,
2024?2031 (USD MILLION) 220
TABLE 239 GCC COUNTRIES: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 221
TABLE 240 MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY REGION, 2024?2031 (USD MILLION) 222
TABLE 241 NORTH AMERICA: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 222
TABLE 242 EUROPE: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET,
2024?2031 (USD MILLION) 223
TABLE 243 ASIA PACIFIC: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 223
TABLE 244 LATIN AMERICA: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 224
TABLE 245 MIDDLE EAST: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET,
BY REGION, 2024?2031 (USD MILLION) 224
TABLE 246 GCC COUNTRIES: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 224
TABLE 247 LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY REGION,
2024?2031 (USD MILLION) 225
TABLE 248 NORTH AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 226
TABLE 249 EUROPE: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
2024?2031 (USD MILLION) 226
TABLE 250 ASIA PACIFIC: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 227
TABLE 251 LATIN AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 227
TABLE 252 MIDDLE EAST: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY REGION, 2024?2031 (USD MILLION) 227
TABLE 253 GCC COUNTRIES: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 228
TABLE 254 ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET,
BY REGION, 2024?2031 (USD MILLION) 228
TABLE 255 NORTH AMERICA: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 229
TABLE 256 EUROPE: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, 2024?2031 (USD MILLION) 229
TABLE 257 ASIA PACIFIC: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 230
TABLE 258 LATIN AMERICA: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 230
TABLE 259 MIDDLE EAST: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY REGION, 2024?2031 (USD MILLION) 230
TABLE 260 GCC COUNTRIES: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 231
TABLE 261 OTHER HTS INSTRUMENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 232
TABLE 262 NORTH AMERICA: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 232
TABLE 263 EUROPE: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 232
TABLE 264 ASIA PACIFIC: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 233
TABLE 265 LATIN AMERICA: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 233
TABLE 266 MIDDLE EAST: OTHER HTS INSTRUMENTS MARKET, BY REGION,
2024?2031 (USD MILLION) 233
TABLE 267 GCC COUNTRIES: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 234
TABLE 268 HTS SOFTWARE & INFORMATICS MARKET, BY REGION, 2024?2031 (USD MILLION) 235
TABLE 269 NORTH AMERICA: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 235
TABLE 270 EUROPE: HTS SOFTWARE & INFORMATICS MARKET, 2024?2031 (USD MILLION) 236
TABLE 271 ASIA PACIFIC: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 236
TABLE 272 LATIN AMERICA: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 237
TABLE 273 MIDDLE EAST: HTS SOFTWARE & INFORMATICS MARKET, BY REGION,
2024?2031 (USD MILLION) 237
TABLE 274 GCC COUNTRIES: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 237
TABLE 275 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TECHNOLOGY,
2024?2031 (USD MILLION) 239
TABLE 276 CELL-BASED SCREENING TECHNOLOGIES MARKET, BY REGION,
2024?2031 (USD MILLION) 240
TABLE 277 NORTH AMERICA: CELL-BASED SCREENING TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 241
TABLE 278 EUROPE: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 241
TABLE 279 ASIA PACIFIC: CELL-BASED SCREENING TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 242
TABLE 280 LATIN AMERICA: CELL-BASED SCREENING TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 242
TABLE 281 MIDDLE EAST: CELL-BASED SCREENING TECHNOLOGIES MARKET,
BY REGION, 2024?2031 (USD MILLION) 242
TABLE 282 GCC COUNTRIES: CELL-BASED SCREENING TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 243
TABLE 283 ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET,
BY REGION, 2024?2031 (USD MILLION) 244
TABLE 284 NORTH AMERICA: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 244
TABLE 285 EUROPE: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 245
TABLE 286 ASIA PACIFIC: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 245
TABLE 287 LATIN AMERICA: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 246
TABLE 288 MIDDLE EAST: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY REGION, 2024?2031 (USD MILLION) 246
TABLE 289 GCC COUNTRIES: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 246
TABLE 290 HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY REGION,
2024?2031 (USD MILLION) 247
TABLE 291 NORTH AMERICA: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 248
TABLE 292 EUROPE: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 248
TABLE 293 ASIA PACIFIC: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 249
TABLE 294 LATIN AMERICA: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 249
TABLE 295 MIDDLE EAST: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET,
BY REGION, 2024?2031 (USD MILLION) 249
TABLE 296 GCC COUNTRIES: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 250
TABLE 297 BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY REGION,
2024?2031 (USD MILLION) 251
TABLE 298 NORTH AMERICA: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 251
TABLE 299 EUROPE: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 252
TABLE 300 ASIA PACIFIC: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 252
TABLE 301 LATIN AMERICA: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 253
TABLE 302 MIDDLE EAST: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET,
BY REGION, 2024?2031 (USD MILLION) 253
TABLE 303 GCC COUNTRIES: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 253
TABLE 304 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET,
BY REGION, 2024?2031 (USD MILLION) 254
TABLE 305 NORTH AMERICA: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 255
TABLE 306 EUROPE: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 255
TABLE 307 ASIA PACIFIC: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 256
TABLE 308 LATIN AMERICA: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 256
TABLE 309 MIDDLE EAST: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY REGION, 2024?2031 (USD MILLION) 256
TABLE 310 GCC COUNTRIES: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 257
TABLE 311 LABEL-FREE SCREENING TECHNOLOGIES MARKET, BY REGION,
2024?2031 (USD MILLION) 258TABLE 312 NORTH AMERICA: LABEL-FREE SCREENING TECHNOLOGIES MARKET,
BY COUNTRY, 2024?2031 (USD MILLION) 258
TABLE 313 EUROPE: LABEL-FREE SCREENING TECHNOLOGIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 259
TABLE 314 ASIA PACIFIC: LABEL-FREE SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 259
TABLE 315 LATIN AMERICA: LABEL-FREE SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 260
TABLE 316 MIDDLE EAST: LABEL-FREE SCREENING TECHNOLOGIES MARKE
T, BY REGION, 2024?2031 (USD MILLION) 260
TABLE 317 GCC COUNTRIES: LABEL-FREE SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 260
TABLE 318 OTHER HTS TECHNOLOGIES MARKET, BY REGION, 2024?2031 (USD MILLION) 261
TABLE 319 NORTH AMERICA: OTHER HTS TECHNOLOGIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 261
TABLE 320 EUROPE: OTHER HTS TECHNOLOGIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 262
TABLE 321 ASIA PACIFIC: OTHER HTS TECHNOLOGIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 262
TABLE 322 LATIN AMERICA: OTHER HTS TECHNOLOGIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 263
TABLE 323 MIDDLE EAST: OTHER HTS TECHNOLOGIES MARKET, BY REGION,
2024?2031 (USD MILLION) 263
TABLE 324 GCC COUNTRIES: OTHER HTS TECHNOLOGIES MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 263
TABLE 325 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY WORKFLOW,
2024?2031 (USD MILLION) 265
TABLE 326 HTS PRODUCTS MARKET FOR PRIMARY SCREENING, BY REGION,
2024?2031 (USD MILLION) 266
TABLE 327 NORTH AMERICA: HTS PRODUCTS MARKET FOR PRIMARY SCREENING,
BY COUNTRY, 2024?2031 (USD MILLION) 266
TABLE 328 EUROPE: HTS PRODUCTS MARKET FOR PRIMARY SCREENING, BY COUNTRY, 2024?2031 (USD MILLION) 267
TABLE 329 ASIA PACIFIC: HTS PRODUCTS MARKET FOR PRIMARY SCREENING,
BY COUNTRY, 2024?2031 (USD MILLION) 267
TABLE 330 LATIN AMERICA: HTS PRODUCTS MARKET FOR PRIMARY SCREENING,
BY COUNTRY, 2024?2031 (USD MILLION) 268
TABLE 331 MIDDLE EAST: HTS PRODUCTS MARKET FOR PRIMARY SCREENING,
BY REGION, 2024?2031 (USD MILLION) 268
TABLE 332 GCC COUNTRIES: HTS PRODUCTS MARKET FOR PRIMARY SCREENING,
BY COUNTRY, 2024?2031 (USD MILLION) 268
TABLE 333 HTS PRODUCTS MARKET FOR ASSAY DEVELOPMENT & OPTIMIZATION,
BY REGION, 2024?2031 (USD MILLION) 269
TABLE 334 NORTH AMERICA: HTS PRODUCTS MARKET FOR ASSAY DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2024?2031 (USD MILLION) 270
TABLE 335 EUROPE: HTS PRODUCTS MARKET FOR ASSAY DEVELOPMENT & OPTIMIZATION,
BY COUNTRY, 2024?2031 (USD MILLION) 270
TABLE 336 ASIA PACIFIC: HTS PRODUCTS MARKET FOR ASSAY DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2024?2031 (USD MILLION) 271
TABLE 337 LATIN AMERICA: HTS PRODUCTS MARKET FOR ASSAY DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2024?2031 (USD MILLION) 271
TABLE 338 MIDDLE EAST: HTS PRODUCTS MARKET FOR ASSAY DEVELOPMENT & OPTIMIZATION, BY REGION, 2024?2031 (USD MILLION) 271
TABLE 339 GCC COUNTRIES: HTS PRODUCTS MARKET FOR ASSAY DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2024?2031 (USD MILLION) 272
TABLE 340 HTS PRODUCTS MARKET FOR HIT CONFIRMATION/SECONDARY SCREENING,
BY REGION, 2024?2031 (USD MILLION) 273
TABLE 341 NORTH AMERICA: HTS PRODUCTS MARKET FOR HIT CONFIRMATION/SECONDARY SCREENING, BY COUNTRY, 2024?2031 (USD MILLION) 273
TABLE 342 EUROPE: HTS PRODUCTS MARKET FOR HIT CONFIRMATION/SECONDARY SCREENING, BY COUNTRY, 2024?2031 (USD MILLION) 274
TABL